Literature DB >> 29280685

Associations among comorbid anxiety, psychiatric symptomatology, and diabetic control in a population with serious mental illness and diabetes: Findings from an interventional randomized controlled trial.

Awais Aftab1, Chetan Bhat2, Douglas Gunzler3, Kristin Cassidy1, Charles Thomas3, Richard McCormick3, Neal V Dawson3, Martha Sajatovic4.   

Abstract

Objective Serious mental illness and type II diabetes mellitus have a high comorbidity, and both have a higher prevalence of anxiety disorders compared to the general population. Targeted Training in Illness Management is a group-based self-management training approach which targets serious mental illness and type II diabetes mellitus concurrently. This analysis examines data from a randomized controlled trial of Targeted Training in Illness Management intervention to examine the impact of comorbid anxiety on baseline psychiatric symptomatology and diabetic control, and on longitudinal treatment outcomes. Methods We conducted secondary analyses on data from a prospective, 60-week, randomized controlled trial testing Targeted Training in Illness Management versus treatment as usual in 200 individuals with serious mental illness and diabetes. Primary outcomes included measures related to serious mental illness symptoms, functional status, general health status, and diabetes control. Measures were compared between those participants with anxiety disorders versus those without anxiety at baseline as well as over time using linear mixed effects analyses. Results Forty seven percent of the participants had one or more anxiety disorders. At baseline, those with an anxiety diagnosis had higher illness severity, depressive, and other psychiatric symptomatology and disability. Diabetic control (HbA1c) was not significantly different at baseline. In the longitudinal analyses, no significant mean slope differences over time (group-by-time interaction effect) between those with anxiety diagnoses and those without in treatment as usual group were found for primary outcomes. Within the Targeted Training in Illness Management arm, those with anxiety disorders had significantly greater improvement in mental health functioning. Those with anxiety comorbidity in the Targeted Training in Illness Management group demonstrated significantly lower HbA1c levels compared to no anxiety comorbidity and also demonstrated a greater improvement in HbA1c over the first 30 weeks compared to those without anxiety comorbidity. Conclusion Comorbid anxiety in serious mental illness and type II diabetes mellitus population is associated with increased psychiatric symptomatology and greater disability. Individuals from this population appear to experience greater improvement in functioning from baseline with the Targeted Training in Illness Management intervention. Anxiety comorbidity in the serious mental illness and type II diabetes mellitus population does not appear to have a negative impact on diabetic control. These complex relationships need further study. Clinical Trials Registration ClinicalTrials.gov: Improving outcomes for individuals with serious mental illness and diabetes (NCT01410357).

Entities:  

Keywords:  comorbidity; medical illness; mental illness; psychiatry

Mesh:

Substances:

Year:  2017        PMID: 29280685      PMCID: PMC5919280          DOI: 10.1177/0091217417749795

Source DB:  PubMed          Journal:  Int J Psychiatry Med        ISSN: 0091-2174            Impact factor:   1.210


  46 in total

1.  Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Wai Tat Chiu; Olga Demler; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

2.  Assessing psychiatric impairment in primary care with the Sheehan Disability Scale.

Authors:  A C Leon; M Olfson; L Portera; L Farber; D V Sheehan
Journal:  Int J Psychiatry Med       Date:  1997       Impact factor: 1.210

3.  Type-2 diabetes mellitus in schizophrenia: increased prevalence and major risk factor of excess mortality in a naturalistic 7-year follow-up.

Authors:  D Schoepf; R Potluri; H Uppal; A Natalwala; P Narendran; R Heun
Journal:  Eur Psychiatry       Date:  2011-05-13       Impact factor: 5.361

4.  Recruiting and Retaining Individuals with Serious Mental Illness and Diabetes in Clinical Research: Lessons Learned from a Randomized, Controlled Trial.

Authors:  Stephanie W Kanuch; Kristin A Cassidy; Neal V Dawson; Melanie Athey; Edna Fuentes-Casiano; Martha Sajatovic
Journal:  J Health Dispar Res Pract       Date:  2016

5.  Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study.

Authors:  Jeff J Guo; Paul E Keck; Patricia K Corey-Lisle; Hong Li; Dongming Jiang; Raymond Jang; Gilbert J L'Italien
Journal:  J Clin Psychiatry       Date:  2006-07       Impact factor: 4.384

6.  Abnormal glycemic homeostasis at the onset of serious mental illnesses: A common pathway.

Authors:  Clemente Garcia-Rizo; Brian Kirkpatrick; Emilio Fernandez-Egea; Cristina Oliveira; Miquel Bernardo
Journal:  Psychoneuroendocrinology       Date:  2016-02-12       Impact factor: 4.905

Review 7.  How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association.

Authors:  Amélie M Achim; Michel Maziade; Eric Raymond; David Olivier; Chantal Mérette; Marc-André Roy
Journal:  Schizophr Bull       Date:  2009-12-03       Impact factor: 9.306

8.  The effect of serious mental illness on the risk of rehospitalization among patients with diabetes.

Authors:  Lydia A Chwastiak; Dimitry S Davydow; Christine L McKibbin; Ellen Schur; Mason Burley; Michael G McDonell; John Roll; Kenn B Daratha
Journal:  Psychosomatics       Date:  2013-12-22       Impact factor: 2.386

Review 9.  Psychiatric comorbidities and schizophrenia.

Authors:  Peter F Buckley; Brian J Miller; Douglas S Lehrer; David J Castle
Journal:  Schizophr Bull       Date:  2008-11-14       Impact factor: 9.306

10.  Correlates of anxiety and depression among patients with type 2 diabetes mellitus.

Authors:  Yatan Pal Singh Balhara; Rajesh Sagar
Journal:  Indian J Endocrinol Metab       Date:  2011-07
View more
  4 in total

1.  Cannabidiol induces antidepressant and anxiolytic-like effects in experimental type-1 diabetic animals by multiple sites of action.

Authors:  Yane Costa Chaves; Karina Genaro; José Alexandre Crippa; Joice Maria da Cunha; Janaína Menezes Zanoveli
Journal:  Metab Brain Dis       Date:  2021-01-19       Impact factor: 3.584

2.  2022 National Standards for Diabetes Self-Management Education and Support.

Authors:  Jody Davis; Amy Hess Fischl; Joni Beck; Lillian Browning; Amy Carter; Jo Ellen Condon; Michelle Dennison; Terri Francis; Peter J Hughes; Stephen Jaime; Ka Hei Karen Lau; Teresa McArthur; Karen McAvoy; Michelle Magee; Olivia Newby; Stephen W Ponder; Uzma Quraishi; Kelly Rawlings; Julia Socke; Michelle Stancil; Sacha Uelmen; Suzanne Villalobos
Journal:  Diabetes Spectr       Date:  2022-03-09

3.  Non-Pharmacological Integrated Interventions for Adults Targeting Type 2 Diabetes and Mental Health Comorbidity: A Mixed-Methods Systematic Review.

Authors:  Elizabeth Tuudah; Una Foye; Sara Donetto; Alan Simpson
Journal:  Int J Integr Care       Date:  2022-06-29       Impact factor: 2.913

4.  Need for improved diabetes support among people with psychiatric disorders and diabetes treated in psychiatric outpatient clinics: results from a Danish cross-sectional study.

Authors:  Lenette Knudsen; Dorte Lindqvist Hansen; Lene Eide Joensen; Rasmus Wibaek; Michael Eriksen Benros; Marit Eika Jørgensen; Gregers Stig Andersen
Journal:  BMJ Open Diabetes Res Care       Date:  2022-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.